Systemic therapy of metastatic breast cancer in postmenopausal patients

被引：0
作者：
Rose, C [1 ]
Lornan, N [1 ]
Killander, F [1 ]
Kinhult, S [1 ]
机构：
[1] Univ Lund Hosp, S-22185 Lund, Sweden
来源：
ADVANCES IN ENDOCRINE THERAPY OF BREAST CANCER, PROCEEDINGS | 2004年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：33 / 46
页数：14
相关论文
共 37 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]   EFFECTS OF MEDROXYPROGESTERONE ACETATE THERAPY ON ADVANCED OR RECURRENT BREAST-CANCER AND ITS INFLUENCES ON BLOOD-COAGULATION AND THE FIBRINOLYTIC SYSTEM [J].
ABE, O ;
ASAISHI, K ;
IZUO, M ;
ENOMOTO, K ;
KOYAMA, H ;
TOMINAGA, T ;
NOMURA, Y ;
OHSHIMA, A ;
AOKI, N ;
TSUKADA, T .
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1995, 25 (08) :701-710
[3]  
[Anonymous], 1986, J Clin Oncol, V4, P186
[4]  
Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO
[5]  
2-Y
[6]   Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate [J].
Buzdar, A ;
Douma, J ;
Davidson, N ;
Elledge, R ;
Morgan, M ;
Smith, R ;
Porter, L ;
Nabholtz, J ;
Xiang, X ;
Brady, C .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3357-3366
[7]  
Clarke M, 1998, LANCET, V351, P1451
[8]  
CLAVEL B, 1982, SEM HOP PARIS, V58, P1919
[9]   A RANDOMIZED TRIAL OF 2ND-LINE HORMONE VS SINGLE AGENT CHEMOTHERAPY IN TAMOXIFEN RESISTANT ADVANCED BREAST-CANCER [J].
DIXON, AR ;
JACKSON, L ;
CHAN, S ;
HAYBITTLE, J ;
BLAMEY, RW .
BRITISH JOURNAL OF CANCER, 1992, 66 (02) :402-404
[10]  
Harris J. R., 2000, DIS BREAST, P749
1234